Vcanbio Cell & Gene Engineering Corp

Vcanbio Cell & Gene Engineering Corp Free Cash Flow

The Free Cash Flow (FCF) of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Nov 21, 2026 is 264.07 M CNY. In the previous year, Free Cash Flow (FCF) was 217.87 M CNY — a change of 21.21% (higher).

Free Cash Flow

264.07 MCNY

YoY

21.21%

Last updated:

Free Cash Flow (FCF) of Vcanbio Cell & Gene Engineering Corp is 2025 264.07 M CNY. Free Cash Flow (FCF) of Vcanbio Cell & Gene Engineering Corp was 2024 217.87 M CNY. It decreases by 21.21% higher compared to the previous year.

The Vcanbio Cell & Gene Engineering Corp Free Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Free Cash Flow
Date
Free Cash Flow
Jan 1, 2018
1.95 M CNY
Jan 1, 2019
118.54 M CNY
Jan 1, 2020
152.64 M CNY
Jan 1, 2021
193.22 M CNY
Jan 1, 2022
162.70 M CNY
Jan 1, 2023
210.40 M CNY
Jan 1, 2024
217.87 M CNY
Jan 1, 2025
264.07 M CNY
The Vcanbio Cell & Gene Engineering Corp Free Cash Flow history
YEARFree Cash FlowYoY
264.07 MCNY+21.21%
217.87 MCNY+3.55%
210.40 MCNY+29.32%
162.70 MCNY-15.79%
193.22 MCNY+26.59%
152.64 MCNY+28.77%
118.54 MCNY+5,982.66%
1.95 MCNY-115.29%
-12.75 MCNY-89.90%
-126.18 MCNY+4.69%
-120.53 MCNY-174.87%
160.98 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vcanbio Cell & Gene Engineering Corp Stock analysis

What does Vcanbio Cell & Gene Engineering Corp do? Vcanbio Cell & Gene Engineering Corp., Ltd. generates revenue through the development and sale of life sciences technology products. The company produces cytokines culture solutions, cosmetics, and detection reagents for domestic markets. Its business segments include cell culture, gene detection and storage, and the production of specialized biological products. The firm's domestic customers primarily purchase these products for research and commercial applications in the life sciences sector. Vcanbio focuses on cell culture and gene detection services, which are integral to its product offerings. The company's cytokines culture solutions are sold to domestic clients in the biotechnology and pharmaceutical industries. Detection reagents are also marketed to domestic laboratories and healthcare providers for diagnostic purposes. The firm leverages its 2,332 full-time employees to support research, development, and production activities. The company's product portfolio includes cosmetics alongside scientific reagents, targeting both consumer and professional markets. Domestic markets remain the primary focus for all sales, with no mention of international operations. Vcanbio's revenue streams are derived from the sale of its core products, which are developed and manufactured in-house. Vcanbio Cell & Gene Engineering Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock

Free Cash Flow (FCF) of Vcanbio Cell & Gene Engineering Corp is 264.07 M CNY in 2025.

Free Cash Flow (FCF) of Vcanbio Cell & Gene Engineering Corp changed from 217.87 M CNY to 264.07 M CNY, representing a 21.21% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow (FCF) Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.

Free Cash Flow is the cash available after capital expenditures. It represents the cash a company can use for dividends, debt reduction, or reinvestment.

FCF = Operating Cash Flow - Capital Expenditures

Free Cash Flow (FCF)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Free Cash Flow (FCF)'s Vcanbio Cell & Gene Engineering Corp historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Vcanbio Cell & Gene Engineering Corp

All Key Metrics — Vcanbio Cell & Gene Engineering Corp